ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.89 Billion KRW | 23.13% |
| 2022 | 9.65 Billion KRW | -55.63% |
| 2021 | 21.76 Billion KRW | -5.26% |
| 2020 | 22.97 Billion KRW | 14.05% |
| 2019 | 20.14 Billion KRW | -6.06% |
| 2018 | 21.44 Billion KRW | -80.53% |
| 2017 | 110.1 Billion KRW | 47.44% |
| 2016 | 74.68 Billion KRW | -11.47% |
| 2015 | 84.35 Billion KRW | 3.61% |
| 2014 | 81.41 Billion KRW | 4.67% |
| 2013 | 77.78 Billion KRW | 5.18% |
| 2012 | 73.95 Billion KRW | 17.33% |
| 2011 | 63.03 Billion KRW | 225.32% |
| 2010 | 19.37 Billion KRW | -54.46% |
| 2009 | 42.54 Billion KRW | 4.85% |
| 2008 | 40.58 Billion KRW | -9.68% |
| 2007 | 44.93 Billion KRW | 60.37% |
| 2006 | 28.01 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 12.44 Billion KRW | 4.68% |
| 2023 Q4 | 11.89 Billion KRW | 21.91% |
| 2023 FY | 11.89 Billion KRW | 23.13% |
| 2023 Q1 | 8.98 Billion KRW | -6.94% |
| 2023 Q2 | 9.01 Billion KRW | 0.27% |
| 2023 Q3 | 9.75 Billion KRW | 8.25% |
| 2022 Q4 | 9.65 Billion KRW | -8.66% |
| 2022 Q1 | 17.79 Billion KRW | 0.0% |
| 2022 Q3 | 10.57 Billion KRW | -18.84% |
| 2022 Q2 | 13.02 Billion KRW | -26.81% |
| 2022 FY | 9.65 Billion KRW | -55.63% |
| 2021 Q2 | 19.55 Billion KRW | -0.29% |
| 2021 FY | 21.76 Billion KRW | -5.26% |
| 2021 Q1 | 19.6 Billion KRW | -14.64% |
| 2021 Q3 | 29.3 Billion KRW | 49.89% |
| 2020 Q1 | 21.82 Billion KRW | 8.33% |
| 2020 Q4 | 22.97 Billion KRW | -3.03% |
| 2020 Q3 | 23.69 Billion KRW | -16.76% |
| 2020 Q2 | 28.46 Billion KRW | 30.44% |
| 2020 FY | 22.97 Billion KRW | 14.05% |
| 2019 Q3 | 17.16 Billion KRW | -17.1% |
| 2019 Q1 | 20.33 Billion KRW | -5.15% |
| 2019 Q2 | 20.7 Billion KRW | 1.82% |
| 2019 FY | 20.14 Billion KRW | -6.06% |
| 2019 Q4 | 20.14 Billion KRW | 17.33% |
| 2018 Q3 | 87.25 Billion KRW | -9.14% |
| 2018 FY | 21.44 Billion KRW | -80.53% |
| 2018 Q4 | 21.44 Billion KRW | -75.43% |
| 2018 Q2 | 96.03 Billion KRW | 3.08% |
| 2018 Q1 | 93.16 Billion KRW | -15.39% |
| 2017 FY | 110.1 Billion KRW | 47.44% |
| 2017 Q1 | 92.79 Billion KRW | 24.26% |
| 2017 Q4 | 110.1 Billion KRW | 15.39% |
| 2017 Q2 | 99.96 Billion KRW | 7.72% |
| 2017 Q3 | 95.41 Billion KRW | -4.54% |
| 2016 Q2 | 83.08 Billion KRW | -6.07% |
| 2016 Q1 | 88.46 Billion KRW | 4.87% |
| 2016 Q4 | 74.68 Billion KRW | -5.47% |
| 2016 Q3 | 79 Billion KRW | -4.91% |
| 2016 FY | 74.68 Billion KRW | -11.47% |
| 2015 FY | 84.35 Billion KRW | 3.61% |
| 2015 Q1 | 84.99 Billion KRW | 4.4% |
| 2015 Q4 | 84.35 Billion KRW | -1.62% |
| 2015 Q2 | 78.83 Billion KRW | -7.25% |
| 2015 Q3 | 85.74 Billion KRW | 8.77% |
| 2014 FY | 81.41 Billion KRW | 4.67% |
| 2014 Q4 | 81.41 Billion KRW | 4.77% |
| 2014 Q1 | 76.27 Billion KRW | -1.93% |
| 2014 Q2 | 75.31 Billion KRW | -1.27% |
| 2014 Q3 | 77.7 Billion KRW | 3.18% |
| 2013 Q2 | 77.83 Billion KRW | 3.52% |
| 2013 FY | 77.78 Billion KRW | 5.18% |
| 2013 Q4 | 77.78 Billion KRW | 1.39% |
| 2013 Q3 | 76.71 Billion KRW | -1.44% |
| 2013 Q1 | 75.19 Billion KRW | 1.67% |
| 2012 FY | 73.95 Billion KRW | 17.33% |
| 2012 Q4 | 73.95 Billion KRW | 0.0% |
| 2011 FY | 63.03 Billion KRW | 225.32% |
| 2011 Q3 | 12.69 Billion KRW | -6.86% |
| 2011 Q2 | 13.62 Billion KRW | 65.95% |
| 2011 Q1 | 8.21 Billion KRW | 0.0% |
| 2010 Q2 | 26.67 Billion KRW | -0.61% |
| 2010 Q3 | 6.27 Billion KRW | -76.47% |
| 2010 FY | 19.37 Billion KRW | -54.46% |
| 2010 Q1 | 26.84 Billion KRW | 0.0% |
| 2009 Q2 | 26.28 Billion KRW | -14.61% |
| 2009 FY | 42.54 Billion KRW | 4.85% |
| 2009 Q3 | 23.81 Billion KRW | -9.41% |
| 2009 Q1 | 30.77 Billion KRW | 0.0% |
| 2008 Q2 | 17.44 Billion KRW | -34.11% |
| 2008 FY | 40.58 Billion KRW | -9.68% |
| 2008 Q3 | 29.99 Billion KRW | 71.9% |
| 2008 Q1 | 26.48 Billion KRW | 0.0% |
| 2007 Q2 | 25.22 Billion KRW | -81.54% |
| 2007 Q1 | 136.68 Billion KRW | 0.0% |
| 2007 Q3 | 27.36 Billion KRW | 8.47% |
| 2007 FY | 44.93 Billion KRW | 60.37% |
| 2006 FY | 28.01 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Green Cross Holdings Corporation | 1856.16 Billion KRW | 99.359% |
| Green Cross Holdings Corporation | 1103.45 Billion KRW | 98.922% |
| Pharmicell Co., Ltd. | 18.79 Billion KRW | 36.727% |
| Green Cross Corporation | 1103.45 Billion KRW | 98.922% |
| GeneOne Life Science, Inc. | 39.51 Billion KRW | 69.908% |
| Celltrion, Inc. | 2791.73 Billion KRW | 99.574% |
| Samsung Biologics Co.,Ltd. | 6215.7 Billion KRW | 99.809% |
| SK bioscience Co.,Ltd. | 148.58 Billion KRW | 91.997% |
| SK Biopharmaceuticals Co., Ltd. | 402.21 Billion KRW | 97.043% |
| Prestige BioPharma Limited | 196.21 Billion KRW | 93.94% |